{"id":"NCT01201356","sponsor":"Novartis Pharmaceuticals","briefTitle":"Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis","officialTitle":"A Single Arm, Open-label, Multicenter Study Evaluating the Long-term Safety and Tolerability of 0.5 mg Fingolimod (FTY720) Administered Orally Once Daily in Patients With Relapsing Forms of Multiple Sclerosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-09-13","primaryCompletion":"2018-10-19","completion":"2018-10-19","firstPosted":"2010-09-14","resultsPosted":"2019-11-07","lastUpdate":"2021-04-21"},"enrollment":4125,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Relapsing Forms of Multiple Sclerosis"],"interventions":[{"type":"DRUG","name":"Fingolimod","otherNames":["FTY720"]}],"arms":[{"label":"Fingolimod 0.5 mg/day","type":"EXPERIMENTAL"}],"summary":"The purpose of this study was to collect long-term safety and tolerability, long-term efficacy, and health outcome data in all patients currently ongoing in the fingolimod multiple sclerosis clinical development program. This study combined all currently ongoing Phase II and III fingolimod extension studies as well as ongoing and newly planned studies into one single long-term extension protocol that provided patients with continuous treatment until fingolimod was registered, commercially available, and reimbursed in the respective countries.","primaryOutcome":{"measure":"Parts I and II: Number of Participants With Adverse Events, Serious Adverse Event, and Death","timeFrame":"Baseline (Part I) to Month 6 Follow-up (Part II), up to 8 years","effectByArm":[{"arm":"Fingolimod 0.5 mg/Day","deltaMin":2125,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":11},"locations":{"siteCount":458,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Czechia","Denmark","Egypt","Estonia","Finland","France","Germany","Greece","Guatemala","Hungary","Ireland","Israel","Italy","Jordan","Malaysia","Netherlands","Norway","Panama","Peru","Poland","Portugal","Romania","Russia","Slovakia","South Africa","South Korea","Spain","Sweden","Switzerland","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["31598139"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":515,"n":4083},"commonTop":["Nasopharyngitis","Headache","Upper respiratory tract infection","Urinary tract infection","Back pain"]}}